ENOV · XBRL financial data

Enovis financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ENOV's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	3,071	3,854	1,563	1,707	2,108	2,248
Cost of goods and services sold	1,783	2,241	694	716	927	903
Gross profit	1,288	1,614	869	991	1,181	1,345
Research and development	34	49	61	75	91	120
Selling, general and administrative	1,087	1,329	773	830	1,027	1,070
Operating income (loss)	162	257	(71)	(66)	(776)	(1,124)
Interest expense	104	73	24	20	57	35
Other income (expense)	—	0	2	26	10	(0)
Income tax expense (benefit)	(6)	67	36	(13)	4	22
Net income (loss)	43	72	(13)	(33)	(825)	(1,184)
Earnings per share, basic USD per share	0.31	0.47	(0.25)	(0.61)	(14.93)	(20.75)
Earnings per share, diluted USD per share	0.31	0.46	(0.25)	(0.61)	(14.93)	(20.75)
Weighted average shares, basic millions of shares	137	153	54	54	55	57
Weighted average shares, diluted millions of shares	139	156	54	54	55	57

† Share count changed about 1/3 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ENOV's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	97	719	24	36	48	36
Accounts receivable	517	639	267	291	407	443
Inventory	565	776	427	469	547	584
Total current assets	1,362	2,303	795	897	1,146	1,207
Property and equipment, net	487	521	237	271	405	507
Right-of-use asset	174	184	67	64	69	72
Goodwill	3,315	3,467	1,984	2,061	1,693	718
Total assets	7,352	8,515	4,273	4,509	4,719	3,835
Accounts payable	330	504	136	132	179	188
Accrued liabilities	454	511	210	237	330	376
Current portion of long-term debt	27	8	219	0	20	35
Total current liabilities	812	1,024	565	370	529	598
Long-term debt	2,204	2,079	40	466	1,309	1,262
Total liabilities	3,764	3,854	823	1,089	2,154	2,343
Retained earnings (accumulated deficit)	517	589	576	542	(283)	(1,467)
Total stockholders' equity	3,543	4,617	3,448	3,418	2,562	1,490
Total liabilities and equity	7,352	8,515	4,273	4,509	4,719	3,835
Common shares outstanding (cover page) millions of shares	118	161	54	55	57	57

† Share count changed about 1/3 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ENOV's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	43	72	(13)	(33)	(825)	(1,184)
Stock-based compensation	29	35	39	34	30	33
Depreciation and amortization	246	263	203	217	928	1,344
Net cash from operating activities	302	356	(56)	135	114	217
Purchases of property and equipment	115	104	105	122	181	197
Net cash from investing activities	(175)	(320)	(176)	(242)	(955)	(179)
Proceeds from issuing common stock	4	745	6	2	2	1
Share repurchases	0	—	0	0	5	4
Repayments of long-term debt	40	0	—	—	—	—
Net cash from financing activities	(132)	585	(465)	128	847	(52)
Net change in cash	(9)	618	(695)	21	3	(12)

† Share count changed about 1/3 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Enovis	13	583	75*	57.7M	—	Q2 FY26 10-QJul 3, 2026
Ufp Technologies	9	174	16*	7.7M	—	Q2 FY26 10-QJun 30, 2026
Lemaitre Vascular	27	not reported	16*	22.9M	—	Q2 FY26 10-QJun 30, 2026
Haemonetics	223	339	52	45.5M	—	Q1 FY27 10-QJun 27, 2026
Teleflex	300	570	not reported	42.4M	—	Q2 FY26 10-QJun 30, 2026
AtriCure	168	154	22*	50.9M	—	Q2 FY26 10-QJun 30, 2026
LivaNova	517	391	67*	55.1M	—	Q2 FY26 10-QJun 30, 2026
Envista Holdings	1,126	731	119*	160.6M	—	Q2 FY26 10-QJul 3, 2026
Artivion	77	126	(1.3)*	48.8M	61.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.